Sun Pharma to invest $25 mn in Pharmazz Inc; raises stake to 22.7 pc
Sun Pharmaceutical Industries Ltd
on Friday said it has entered into an agreement with US-based
Pharmazz Inc
to invest up to USD 25 million, resulting in increasing its stake in the company to 22.7 per cent. The investment triggers conversion of earlier investment through SAFE (simple agreement for future equity) resulting in aggregate stake of up to 22.7 per cent in Pharmazz on a fully diluted basis, the company said in a regulatory filing.
The first tranche of USD 10 million, along with the balance of USD 7.5 million out of SAFE tranche 2 investment, will be invested on or before May 31, 2025. The second tranche of USD 15 million will be invested on or before November 30, 2025 or such other mutually agreed date, it added.
Pharmazz Inc is a
biopharmaceutical company
, developing two leading
drug candidates
,
Sovateltide
for treatment of acute cerebral ischemic stroke and
Centhaquine
for treatment of hypovolemic shock.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Ethiopia: Jewelry On Sale For Half Price! (See Price List)
Luxury Jewelry | search ads
Undo
Both products are approved in India and marketed through partners under brands Tyvalzi (Sovateltide) and Lyfaquin (Centhaquine), and are being developed for USA and other markets, it added.
Subsequent to the investment, Sun Pharma will receive an option to negotiate licensing of Sovateltide for marketing and distribution in certain developed market countries.
Live Events
The company has already received exclusive right to licence Sovateltide for marketing and distribution in certain emerging market countries, it added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Deccan Herald
27 minutes ago
- Deccan Herald
Sensex climbs 108.02 points in early trade; Nifty up 38.7 points
Sensex closed higher by 123 points while Nifty rose for a sixth consecutive day on Wednesday following a rally in global markets amid optimism over US-China trade talks and foreign fund inflows.
Economic Times
27 minutes ago
- Economic Times
I-Sec maintains Add on Marico, target price Rs 740: ICICI Securities
ICICI Securities maintains an Add call on Marico, setting a target price of Rs 740. The brokerage anticipates a revenue, EBITDA, and PAT CAGR of 11%, 14%, and 11% respectively, from FY25-27E. This growth is expected to be driven by market share gains, expansion in foods and premium personal care, and strong international performance. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads (Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.) ICICI Securities has maintained the Add call on Marico with a target price of Rs 740. The current market price of Marico is Rs 704.3. Marico, incorporated in 1988, is a Large Cap company wiht a market cap of Rs 91049.83 crore, operating in the FMCG key products/revenue segments include Edible Oil, Others, Personal Care, Export Incentives, Scrap for the year ending the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 2777.00 crore, down -2.08 % from last quarter Total Income of Rs 2836 crore and up 21.11% from last year same quarter Total Income of Rs 2293 crore. The company has reported net profit after tax of Rs 345.00 crore in the latest company's top management includes Mariwala, Bali, Purohit, Vasudeva, Barve, Sankaranarayanan, Mariwala, Mariwala, Khattau, Gupta, Bharti Mittal. Company has B S R & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 130 crore shares Securities expects Marico to deliver revenue / EBITDA / PAT CAGR of 11/14/11 (%) over FY25-27E. In their view, Marico could deliver double-digit revenue growth over medium term through consistent outperformance vs peers driven by 1) market share gains in core India portfolios, 2) accelerated growth in foods and premium personal care, and 3) double-digit constant currency growth in international business. The brokerage also expects operating margin to improve in medium term with moderation in RM inflation, leverage benefits and premiumisation of the portfolio. They maintain ADD with a DCF-based target price of Rs 740. At the target price, the stock will trade at 47x P/E multiple for Mar' downside risks are higher-than-expected inflation in copra prices, execution misses and risks associated with leadership changes. Upside risk includes Better-than-expected performance in D2C brands and faster-than-expected recovery in core held 59.05 per cent stake in the company as of 31-Mar-2025, while FIIs owned 22.09 per cent, DIIs 13.98 per cent.
Time of India
42 minutes ago
- Time of India
Stock market today: Nifty50 opens flat; BSE Sensex above 82,500
Market sentiment could be influenced by positive progress in US-China trade relation. (AI image) Stock market today: Nifty50 and BSE Sensex , the Indian equity benchmark indices, opened flat in trade on Thursday, While Nifty50 opened above 25,150, BSE Sensex was above 82,500. At 9:18 AM, Nifty50 was trading at 25,155.95, up 15 points or 0.058%. BSE Sensex was at 82,549.09, up 34 points or 0.041%. Market sentiment could be influenced by positive progress in US-China trade relations and India-EU Free Trade Agreement negotiations. VK Vijayakumar, Chief Investment Strategist, Geojit Investments Limited says, 'The recent flattish trend in the market is likely to continue in the near-term since there are no clear positive triggers that can push the market much higher. There are reports of a possible agreement between the U.S. and China. But the Chinese haven't officially confirmed anything. President Trump is talking about 55% tariff on China and 10% tariff on U.S. President Trump's credibility being what it is, it would be too early to discount this as positive for markets. Also President Trump has declared that he will be sending letters to trade partners in the next two weeks setting universal tariffs. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Are you 18-79 with no funeral insurance? Talk to NZ Seniors today NZ Seniors Get Quote Undo Market participants will be waiting and watching for clarity on this. The tariff crisis is not yet over. The spike in Brent crude to $70 on heightened security risks in the Middle East is a negative for India. Sectors like paints, adhesives, tyres and aviation are likely to respond negatively to this while ONGC and Oil India can respond positively." Wednesday saw the S&P 500 close lower as Middle East tensions concerned investors, whilst a moderate inflation report eased worries about tariff-related price increases. Investors await further information on China-US trade discussions. US index futures and the dollar weakened after President Donald Trump announced plans to implement unilateral tariffs within two weeks, escalating trade tensions. Oil prices increased due to the Middle East situation. Gold prices advanced on Thursday due to heightened Middle East tensions driving safe-haven demand, whilst lower-than-anticipated US inflation figures strengthened the likelihood of Federal Reserve interest rate reductions. Oil prices reached their highest level in over two months on Thursday following US President Donald Trump's announcement regarding US personnel withdrawal from the Middle East, sparking concerns about potential Iranian supply disruptions. Foreign portfolio investors sold shares worth Rs 446 crore net on Wednesday, whilst DIIs purchased Rs 1585 crore net. FIIs' position in futures market decreased from Rs 93,024 crore net short on Tuesday to Rs 86,594 crore on Wednesday. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
